FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200362244> ?p ?o ?g. }

• W3200362244 abstract "During the last year, mass screening campaigns have been carried out to identify immunological response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and establish a possible seroprevalence. The obtained results gained new importance with the beginning of the SARS-CoV-2 vaccination campaign, as the lack of doses has persuaded several countries to introduce different policies for individuals who had a history of COVID-19. Lateral flow assays (LFAs) may represent an affordable tool to support population screening in low-middle-income countries, where diagnostic tests are lacking and epidemiology is still widely unknown. However, LFAs have demonstrated a wide range of performance, and the question of which one could be more valuable in these settings still remains. We evaluated the performance of 11 LFAs in detecting SARS-CoV-2 infection, analyzing samples collected from 350 subjects. In addition, samples from 57 health care workers collected at 21 to 24 days after the first dose of the Pfizer-BioNTech vaccine were also evaluated. LFAs demonstrated a wide range of specificity (92.31% to 100%) and sensitivity (50% to 100%). The analysis of postvaccination samples was used to describe the most suitable tests to detect IgG response against S protein receptor binding domain (RBD). Tuberculosis (TB) therapy was identified as a potential factor affecting the specificity of LFAs. This analysis identified which LFAs represent a valuable tool not only for the detection of prior SARS-CoV-2 infection but also for the detection of IgG elicited in response to vaccination. These results demonstrated that different LFAs may have different applications and the possible risks of their use in high-TB-burden settings. IMPORTANCE Our study provides a fresh perspective on the possible employment of SARS-CoV-2 LFA antibody tests. We developed an in-depth, large-scale analysis comparing LFA performance to enzyme-linked immunosorbent assay (ELISA) and electrochemiluminescence immunoassay (ECLIA) and evaluating their sensitivity and specificity in identifying COVID-19 patients at different time points from symptom onset. Moreover, for the first time, we analyzed samples of patients undergoing treatment for endemic poverty-related diseases, especially tuberculosis, and we evaluated the impact of this therapy on test specificity in order to assess possible performance in TB high-burden countries." @default.
• W3200362244 created "2021-09-27" @default.
• W3200362244 creator A5019924761 @default.
• W3200362244 creator A5029468493 @default.
• W3200362244 creator A5031847901 @default.
• W3200362244 creator A5037317031 @default.
• W3200362244 creator A5042521470 @default.
• W3200362244 creator A5045341602 @default.
• W3200362244 creator A5053847558 @default.
• W3200362244 creator A5069038536 @default.
• W3200362244 creator A5072483876 @default.
• W3200362244 creator A5090984399 @default.
• W3200362244 date "2021-10-31" @default.
• W3200362244 modified "2023-10-17" @default.
• W3200362244 title "SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings" @default.
• W3200362244 cites W2138473951 @default.
• W3200362244 cites W3021590963 @default.
• W3200362244 cites W3028872489 @default.
• W3200362244 cites W3035189381 @default.
• W3200362244 cites W3038707046 @default.
• W3200362244 cites W3040552450 @default.
• W3200362244 cites W3042918038 @default.
• W3200362244 cites W3047175793 @default.
• W3200362244 cites W3048683141 @default.
• W3200362244 cites W3081055927 @default.
• W3200362244 cites W3088809187 @default.
• W3200362244 cites W3092301564 @default.
• W3200362244 cites W3123021790 @default.
• W3200362244 cites W3125733744 @default.
• W3200362244 cites W3127081034 @default.
• W3200362244 cites W3133467376 @default.
• W3200362244 cites W3133987520 @default.
• W3200362244 doi "https://doi.org/10.1128/spectrum.00250-21" @default.
• W3200362244 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8557824" @default.
• W3200362244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34549999" @default.
• W3200362244 hasPublicationYear "2021" @default.
• W3200362244 type Work @default.
• W3200362244 sameAs 3200362244 @default.
• W3200362244 citedByCount "6" @default.
• W3200362244 countsByYear W32003622442021 @default.
• W3200362244 countsByYear W32003622442022 @default.
• W3200362244 countsByYear W32003622442023 @default.
• W3200362244 crossrefType "journal-article" @default.
• W3200362244 hasAuthorship W3200362244A5019924761 @default.
• W3200362244 hasAuthorship W3200362244A5029468493 @default.
• W3200362244 hasAuthorship W3200362244A5031847901 @default.
• W3200362244 hasAuthorship W3200362244A5037317031 @default.
• W3200362244 hasAuthorship W3200362244A5042521470 @default.
• W3200362244 hasAuthorship W3200362244A5045341602 @default.
• W3200362244 hasAuthorship W3200362244A5053847558 @default.
• W3200362244 hasAuthorship W3200362244A5069038536 @default.
• W3200362244 hasAuthorship W3200362244A5072483876 @default.
• W3200362244 hasAuthorship W3200362244A5090984399 @default.
• W3200362244 hasBestOaLocation W32003622441 @default.
• W3200362244 hasConcept C107130276 @default.
• W3200362244 hasConcept C126322002 @default.
• W3200362244 hasConcept C159047783 @default.
• W3200362244 hasConcept C159654299 @default.
• W3200362244 hasConcept C203014093 @default.
• W3200362244 hasConcept C22070199 @default.
• W3200362244 hasConcept C2778494684 @default.
• W3200362244 hasConcept C2779134260 @default.
• W3200362244 hasConcept C2908647359 @default.
• W3200362244 hasConcept C3007834351 @default.
• W3200362244 hasConcept C3008058167 @default.
• W3200362244 hasConcept C45189115 @default.
• W3200362244 hasConcept C524204448 @default.
• W3200362244 hasConcept C71924100 @default.
• W3200362244 hasConcept C99454951 @default.
• W3200362244 hasConceptScore W3200362244C107130276 @default.
• W3200362244 hasConceptScore W3200362244C126322002 @default.
• W3200362244 hasConceptScore W3200362244C159047783 @default.
• W3200362244 hasConceptScore W3200362244C159654299 @default.
• W3200362244 hasConceptScore W3200362244C203014093 @default.
• W3200362244 hasConceptScore W3200362244C22070199 @default.
• W3200362244 hasConceptScore W3200362244C2778494684 @default.
• W3200362244 hasConceptScore W3200362244C2779134260 @default.
• W3200362244 hasConceptScore W3200362244C2908647359 @default.
• W3200362244 hasConceptScore W3200362244C3007834351 @default.
• W3200362244 hasConceptScore W3200362244C3008058167 @default.
• W3200362244 hasConceptScore W3200362244C45189115 @default.
• W3200362244 hasConceptScore W3200362244C524204448 @default.
• W3200362244 hasConceptScore W3200362244C71924100 @default.
• W3200362244 hasConceptScore W3200362244C99454951 @default.
• W3200362244 hasFunder F4320307856 @default.
• W3200362244 hasIssue "2" @default.
• W3200362244 hasLocation W32003622441 @default.
• W3200362244 hasLocation W32003622442 @default.
• W3200362244 hasLocation W32003622443 @default.
• W3200362244 hasLocation W32003622444 @default.
• W3200362244 hasLocation W32003622445 @default.
• W3200362244 hasOpenAccess W3200362244 @default.
• W3200362244 hasPrimaryLocation W32003622441 @default.
• W3200362244 hasRelatedWork W3036305013 @default.
• W3200362244 hasRelatedWork W3121286195 @default.
• W3200362244 hasRelatedWork W3127693599 @default.
• W3200362244 hasRelatedWork W3176864053 @default.
• W3200362244 hasRelatedWork W3198183218 @default.
• W3200362244 hasRelatedWork W4205317059 @default.
• W3200362244 hasRelatedWork W4205810683 @default.

• next